SOLICITATION NOTICE
66 -- Acquisition of a 700MHz Nuclear Magnetic Resonance (NMR) Spectrometer for Metabolomics Analyses
- Notice Date
- 7/29/2017
- Notice Type
- Presolicitation
- NAICS
- 334516
— Analytical Laboratory Instrument Manufacturing
- Contracting Office
- Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E128, Rockville, Maryland, 20852, United States
- ZIP Code
- 20852
- Solicitation Number
- N02RC72558-76
- Archive Date
- 8/10/2017
- Point of Contact
- Catherine Muir, Phone: (240) 276-5434
- E-Mail Address
-
muirca@mail.nih.gov
(muirca@mail.nih.gov)
- Small Business Set-Aside
- N/A
- Description
- Contracting Office Address: Department of Health and Human Services, National Institutes of Health, National Cancer Institute, Office of Acquisitions, 9609 Medical Center Drive, Room 1E144, Bethesda, MD 20892, USA. Description: National Cancer Institute (NCI), Center for Cancer Research (CCR), Metabolomics Core (MC), plans to procure on a sole source basis a 700MHz NMR spectrometer for metabolomics analyses that is manufactured by Bruker Biospin Corp.; 15 Fortune Drive; Billerica, MA 01821 USA. The response close date of this notice for this requirement is in accordance with FAR 5.203(a)(1). This acquisition will be processed under FAR Part 12 - Acquisition for Commercial Items and in accordance with simplified acquisition procedures as stated in FAR Part 13.106-1(b)(2), and is exempt from the requirements of FAR Part 6. The North American Industry Classification System code is 334516 and the business size standard is 1,000 employees. Only one award will be made as a result of this solicitation. This will be awarded as a firm fixed price type contract. The period of performance is thirteen (13) months from the date of award. The services are non-severable in nature. It has been determined there are no opportunities to acquire green products or services for this procurement. This acquisition will fulfill unmet needs of scientists in the Urologic Oncology Branch (UOB), Neuro-Oncology Branch (NOB), and Radiation Biology Branch (RBB). It will be utilized as a Metabolomics Core facility instrument as the NCI/CCR develops and expands its in-house metabolomics capabilities. Specifically, the RBB's research activities are focused on pre-clinical basic science research aimed at identifying and incorporating novel approaches to cancer treatment, evaluation, and prevention. A variety of approaches are evaluated at the molecular, biochemical, cellular, and physiological levels including the impact of the tumor microenvironment and metabolic mutations to improve cancer treatment. Intentional or accidental exposure of humans to ionizing radiation or a course of definitive radiation therapy can lead to cancer induction or second malignancies. Research studies are directed to identify interventions to delay or prevent radiation-induced cancer after the exposure has occurred. Emphasis is placed on gaining a better understanding of the mechanisms of cell killing and protection and the activation/inhibition of complex signaling pathways mediated by oxidative stress, including ionizing radiation, reactive oxygen species (ROS), and reactive nitrogen species (RNS). Metabolomics is the global, systematic identification and quantitation of metabolites in a given organism or biological samples, including cells, tissue, blood, and urine. The enhanced atomic-level resolution of metabolic analysis provided by nuclear magnetic resonance spectroscopy (NMR) along with powerful chemometric software allows for the simultaneous determination and comparison of thousands of chemical entities. At present, existing intramural resources at the NCI for standardized, high quality metabolomics analyses are limited due to a lack of dedicated instrumentation configured for metabolomics. Although there are several NMR spectrometers installed in Building 10, the CCR currently does not operate an NMR that is configured, optimized and dedicated for metabolomics applications such as targeted mechanistic Stable Isotope-Resolved tracer studies in cultured cells and tissues as well as targeted and untargeted NMR-based discovery and diagnostic studies in patient-derived surgical specimens, biopsies, and biofluids such as plasma, urine and cerebrospinal fluid. The NMR spectrometer specified in this Acquisition is fine-tuned for the needs of proton-detected 13C or 15N stable isotope experiments as well as rapid analysis of intact surgical tissue and biopsy specimens by high resolution magic angle spinning (HR-MAS) NMR. The Contractor shall provide the following salient physical, functional, and performance characteristics, inclusive of hardware and/or software specifications, that are deemed essential to the needs of the Government: • 16.44T superconducting magnet system with 5.4cm central bore, with integrated magnet shimming and locking systems, operational frequency of 700MHz. • 3mm ultra-high sensitivity helium-cooled Inverse Triple Resonance CryoProbe • 5mm room temperature Inverse Triple Resonance Probe • 5mm Multinuclear Broadband Observe Probe. • Refrigerated 24-place automated sample changer • high-resolution magic angle spinning (HR-MAS) probe and regulation unit • BCU-II pre-cooling and stabilization unit, needed for high resolution operation of the CryoProbe and HR-MAS probe. • AssureNMR Summit software package with 15 year license, needed for analysis of sample spectra, determination of instrument performance, and untargeted metabolomics analyses. • Test and system suitability sample sets, required for determination of instrument performance. DELIVERY / INSTALLATION Delivery address: National Institutes of Health National Cancer Institute Center for Cancer Research, Center for Cancer Metabolism 9000 Rockville Pike Building 10, Room 3B32 Bethesda, MD 20892 The magnet, console, and all associated machinery and instrumentation shall be delivered within seven (7) months of purchase order award. The specially-made 3mm Triple Resonance Inverse Detection CryoProbe shall be delivered within thirteen (13) months after receipt of order. TRAINING This acquisition includes a full battery of instrument calibration standards to be used during and following installation. Also included are eight days of training courses for no less than three (3) CCM facility staff. PAYMENT Payment shall be made in arrears after delivery, installation, inspection and acceptance, and successful completion of the required training stated above. Payment authorization requires submission and approval of invoices to the NCI Technical Point of Contact and the NIH Office of Financial Management (OFM), in accordance with the payment provisions in the order. This equipment is manufactured by Bruker Biospin Corp. The proposed source is the only known source on the market that provides an instrument with all of the technical requirements stated in the Statement of Need required for the cancer metabolism research being conducted at the NCI. Although several high field NMR spectrometers currently exist in the NCI, and in the NIH Intramural Program as a whole, nearly all of these spectrometers are configured for protein structural and dynamic studies, which typically involve scans of a single sample lasting up to several days in duration. Moreover, these spectrometers are not configured for high-throughput sample measurements required by the MC. Therefore, none of these instruments are currently configured for dedicated targeted and untargeted metabolomics protocols and procedures conducted by the MC. In addition, none of these instruments are available for the MC's use and method development on a regular basis. Furthermore, there is no comparable technology to nuclear magnetic resonance spectroscopy nor other viable sources available in order to advance the MC's scientific mission. This notice is not a request for competitive quotation. However, if any interested party, especially small businesses, believes it can meet the above requirement, it may submit a capability statement, proposal, or quotation, which shall be considered by the agency. The statement of capabilities and any other information furnished must be in writing and must contain material in sufficient detail to allow NCI to determine if the party can perform the requirement. Responses must be received in the contracting office by 1:00PM EDT, on Aug. 9, 2017. All responses and questions must be in writing and faxed (240) 276-5401 or emailed to Catherine Muir, Contracting Officer via electronic mail at muirca@mail.nih.gov. A determination by the Government not to compete this proposed requirement based upon responses to this notice is solely within the discretion of the Government. Information received will be considered solely for the purpose of determining whether to conduct a competitive procurement. No collect calls will be accepted. In order to receive an award, Contractors must be registered and have valid, current Entity Record, including current Representations and Certifications, in the System for Award Management (SAM) through SAM.gov. Reference: N02RC72558-76 on all correspondence.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/HHS/NIH/RCB/N02RC72558-76/listing.html)
- Record
- SN04604143-W 20170731/170729230145-7e635a3c3e2a064ea33adbcd98f81050 (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |